Hookipa Pharma (HOOK) Projected to Post Quarterly Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Hookipa Pharma to post earnings of ($0.69) per share and revenue of $6.50 million for the quarter.

Hookipa Pharma Price Performance

Shares of NASDAQ:HOOK opened at $1.25 on Thursday. The business’s 50 day moving average price is $1.78 and its 200-day moving average price is $2.94. Hookipa Pharma has a 1 year low of $1.11 and a 1 year high of $10.50. The firm has a market capitalization of $15.07 million, a price-to-earnings ratio of -0.34 and a beta of 0.71.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Royal Bank of Canada downgraded shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $48.00 to $2.00 in a report on Friday, December 20th. HC Wainwright reaffirmed a “neutral” rating on shares of Hookipa Pharma in a research note on Friday, January 10th. Finally, JMP Securities cut their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research note on Thursday, November 21st.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.